Gap between 2nd Covid shot and booster likely to be 9-12 months: Report

The nitty-gritty of the gaps for the vaccines currently being used in India's inoculation programme Covishield and Covaxin is being worked out, and a final decision over this will be taken soon

Coronavirus vaccine, Covid-19 vaccines
Press Trust of India New Delhi
2 min read Last Updated : Dec 26 2021 | 12:33 PM IST

The gap between the second dose of COVID-19 vaccine and the third, which is being called a "precaution dose", is likely to be nine to 12 months, official sources said on Sunday.

The nitty-gritty of the gaps for the vaccines currently being used in India's inoculation programme Covishield and Covaxin is being worked out, and a final decision over this will be taken soon, they said.

Prime Minister Narendra Modi, in a televised address to the nation on Saturday night, announced that vaccination against COVID-19 for children between 15-18 years will start from January 3, while "precaution dose" for healthcare and frontline workers would be administered from January 10.

The decisions came amid rising Covid cases linked to the Omicron variant of the virus.

Modi said the precaution dose will also be available for citizens above 60 years of age and with comorbidities on the advice of their doctor from January 10 next year as well.

The precaution dose denotes a third dose of the vaccine for the fully vaccinated but Modi refrained from using the term "booster dose", as it is generally referred.

"The gap between the second and the precautionary dose of Covid vaccine is likely to be nine to 12 months with the immunisation division and the National Technical Advisory Group on Immunisation (NTAGI) discussing on these lines," a source said.

More than 61 per cent of India's adult population has received both doses of the vaccine. Similarly, about 90 per cent of the adult population has received the first dose.

With the administration of 32,90,766 vaccine doses in the last 24 hours, the cumulative COVID-19 vaccine doses administered in the country has exceeded 141.37 crore, as per provisional reports till 7 am.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronCoronavirus VaccineVaccination

First Published: Dec 26 2021 | 12:33 PM IST

Next Story